Sayang
Via Valen
Intro : A# C Am Dm Gm C F
F Am
Sayang opo kowe krungu
Dm
jerit e ati ku
Am
mengharap engkau kembali
A# C Am Dm
sayang nganti memutih rambutku
Gm C F
ra bakal luntur tresnoku
F
wes ta cobo ngelalekne jenengmu soko atiku
Am
sak tenan e ra ngapusi isih tresno sliramu
Dm
duko pujane ati nanging koe ora ngerti
Am
kowe wes tak wanti wanti malah jebul
A#
saiki koe mblenjani janji
Am Dm
jare sehidup semati nanging opo bukti
A# C
kowe medot tresnoku demi wedoan liyo
F
yowes ora popo insya Allah aku iso lilo
Dm Am A#
meh sambat kaleh sinten yen sampun mekaten
C F
merana uripku
A# C Am Dm
aku welasno kangmas aku mesakno aku
A# C
aku nangis nganti metu eluh getih putih
Chorus :
F Am
sayang opo kowe krungu
Dm
jeri e ati ku
Am
mengharap engkau kembali
A# C Am Dm
sayang nganti memutih rambutku
A# C F
ra bakal luntur tresnoku
F
sayang opo krungu tangis e ati ku
Am
mengharap koe bali nang jero ati iki
Dm
nganti rambutku putih tangis eloh dadi getih
Am
mbok yo gek ndang bali nglakoni tresno suci
A# C
aku marang sliramu jero ning ati
aku ra isoh ngapusi sak tenan e neng ati
A# C
mung kango sliramu cinta mu tetap abadi
F
selamanya sampai akhir hanyat ini
Dm Am A#
meh sambat kaleh sinten ye sampun mekaten
C F
merana uripku
A# C Am Dm
aku welasno kangmas aku mesakno aku
A# C
aku nangis nganti metu eluh getih putih
Chorus :
F Am
sayang opo kowe krungu
Dm
jeri e ati ku
Am
mengharap engkau kembali
A# C Am Dm
sayang nganti memutih rambutku
A# C F
ra bakal luntur tresnoku
F A#
percoyo opo bebujamu
C F
cintamu kan tetap abadi
It's the Catch-22 of clinical trials: to protect pregnant women and children from the risks of untested drugs....we don't test drugs adequately for them. In the last few decades , we've been more concerned about the harms of research than of inadequately tested treatments for everyone, in fact. But for "vulnerable populations," like pregnant women and children, the default was to exclude them. And just in case any women might be, or might become, pregnant, it was often easier just to exclude us all from trials. It got so bad, that by the late 1990s, the FDA realized regulations and more for pregnant women - and women generally - had to change. The NIH (National Institutes of Health) took action too. And so few drugs had enough safety and efficacy information for children that, even in official circles, children were being called "therapeutic orphans." Action began on that, too. There is still a long way to go. But this month there was a sign that ...
Comments
Post a Comment